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a b s t r a c t
Brachytherapy plays an essential role in the curative intent management of locally advanced
cervical cancer. The introduction of the magnetic resonance (MR) as a preferred image
modality and the development of new type of applicators with interstitial components have
further improved its benefits.
The aim of this work is to review the current status of one important aspect in the cervix
cancer brachytherapy procedure, namely catheter reconstruction.
MR compatible intracavitary and interstitial applicators are described. Considerations
about the use of MR imaging (MRI) regarding appropriate strategies for applicator recon-
struction, technical requirements, MR sequences, patient preparation and applicator
commissioning are included.
It is recommendable to perform the reconstruction process in the same image study
employed by the physician for contouring, that is, T2 weighted (T2W) sequences. Never-
theless, a clear identification of the source path inside the catheters and the applicators is
a challenge when using exclusively T2W sequences. For the intracavitary component of the
implant, sometimes the catheters may be filled with some substance that produces a high
intensity signal on MRI. However, this strategy is not feasible for plastic tubes or titanium
needles, which, moreover, induce magnetic susceptibility artifacts. In these situations, the
use of applicator libraries available in the treatment planning system (TPS) is useful, since
they not only include accurate geometrical models of the intracavitary applicators, but also
recent developments have made possible the implementation of the interstitial component.
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Another strategy to improve the reconstruction process is based on the incorporation of MR
markers, such as small pellets, to be used as anchor points.
Many institutions employ computed tomography (CT) as a supporting image modality. The
registration of CT and MR image sets should be carefully performed, and its uncertainty
previously assessed. Besides, an important research work is being carried out regarding the
use of ultrasound and electromagnetic tracking technologies.
© 2018 Greater Poland Cancer Centre. Published by Elsevier Sp. z o.o. All rights reserved.
1. Background
Brachytherapy (BT) plays an essential role in the curative
intent management of locally advanced cervical cancer for
which the conventional approach consists of external beam
radiotherapy (EBRT) with concurrent chemotherapy followed
by BT. Excellent local control rates are achieved with this
scheme. Many authors have reported increasing levels of
tumor control while decreasing rates in normal tissue toxic-
ity when BT is involved in the overall course of the treatment,
demonstrating its efficacy.1–3
Furthermore, the introduction of image based planning in
BT procedures has proven to have a huge impact in the clini-
cal outcome improvement of the patients undergoing this type
of procedures.4 During the last decade, BT of cervical cancer
has evolved from a 2D approach and point based prescription,
to 3D or 4D image based treatment planning, magnetic reso-
nance imaging (MRI) being the preferred image modality, and
volume based prescription, which allows taking into account
the changes due to the tumor response during the treat-
ment. In 2016, the International Commission on Radiation
Units and Measurements, in collaboration with the Groupe
Européen de Curithérapie – European Society for Radiothe-
rapy and Oncology (GEC-ESTRO), published the ICRU report no
89,5 where essentials for image acquisition, tumor contouring,
dose calculation and treatment planning procedures such as
applicator reconstruction are described.
The advent of the image guided adaptive brachytherapy
(IGABT) has further improve local control rates.6–12 Precise tar-
get volume contouring on MRI and adaptive volume based
(instead of point based) treatment planning underlies the good
outcomes.
Some studies have analyzed the use of high conformal
techniques, such as IMRT or SBRT, with the objective of
replacing BT procedures.13–15 Nevertheless, these advanced
techniques of EBRT are not able to produce dose distributions
with as high doses and steep dose gradients delivered to the
target, while minimizing dose to the critical structures as dose
distributions typically produced in BT.16 Furthermore, lower
survival rates have been reported when BT is not carried out.
Undoubtedly, as stated in an article of Tanderup et al.16, high
quality IGABT is of crucial importance in the management of
locally advanced cervical cancer.
International recommendations advocate the use of MRI
as the preferred image modality due to its superior soft tissue
contrast.17–19 Therefore, applicators must be MR compatible.
Additionally, it has been evidenced that the interstitial com-
ponent, added to the intracavitary one, allows for a higher
conformity and organs at risk dose sparing.12,20,21 In this work,
we have reviewed the commercially available applicators as
well as some in-house developed ones, focusing on those hav-
ing interstitial components.
Ideally, the reconstruction of the applicator geometry and
its matching with the patient anatomy should be done in the
same image study in which the physician defines the vol-
umes to be treated, that is T2 weighted (T2W) MRI. However,
the availability of the MR may be limited and, in addition,
the identification of the source trajectory inside the void
signal produced by the air filled interior of the applicators
is difficult. Therefore, the use of other image modalities is
sometimes beneficial in the reconstruction process. In this
work a literature review is performed in order to gather
information about how to facilitate the reconstruction proce-
dure, including direct reconstruction, applicator library based
reconstruction and electromagnetic tracking. The use of com-
plementary or alternative image modalities is also addressed,
such as CT and ultrasonography (US).
The authors want to emphasize that the different appli-
cators or commercially available products mentioned in this
work are presented merely with and illustrative purpose and
do not represent any recommendation about their use in clin-
ical practice.
2. MR compatible applicators for locally
advanced cervical cancer
Bulky infiltrative extensive disease in cervix carcinoma with
lateral parametrial invasion requires an interstitial compo-
nent combined with the intracavitary one in the BT treatment
in order to optimize properly the dose distribution in this
adverse asymmetrical topography.22–24
In this context, BT companies provide a considerable vari-
ety of mixed intracavitary-interstitial MR compatible cervix
applicators in three modalities: interstitial-vaginal (IS-V),
interstitial-perineal (IS-P) and interstitial-vaginal-perineal
(IS-V&P). The first group (IS-V) includes ovoids with tandem21
and ring with tandem.20 In the second group, Martinez
et al.25 developed a commercial interstitial-perineal (IS-P)
template with vaginal obturator. Varian (VMS, Palo Alto,
CA, USA) developed gynecological templates (Kelowna) for
interstitial implants. Some users have created their own
templates26,27 in order to suit their clinical requirements and
facilitate the distribution of needles across the perineum. A
prototype applicator, with combined perineal template and
vaginal cylinder, is the Nice applicator, that was developed
by Hannoun-Levi et al.28 In the third group, (IS-V&P) one
applicator from Bebig (Eckert & Ziegler, Berlin, Germany)
reports of practical oncology and radiotherapy 2 3 ( 2 0 1 8 ) 547–561 549
combines the perineal template and vaginal cylinder, with
needles in the vaginal obturator. The Venezia applicator,
which appeared recently in the market, is a solution bringing
together vaginal and perineal interstitial elements (IS-V&P)
(https://www.elekta.com/brachytherapy/applicators.html).
3D printing expands the possibilities of interstitial vaginal
BT allowing modification and personalization of commercial
solutions according to patient anatomy.29,30
In the IS-V line, Fokdal et al.29 use a biocompatible, 3D
printing material in a study on virtual planning of the inter-
stitial component to generate a custom cap with perforations
for twelve needles, which is subsequently placed on a tandem
applicator. Similarly, Lindegaard et al.30 report the clinical use
of a ring template created by 3D printing and assembled to a
tandem applicator from Varian (VMS, Palo Alto, CA. USA). In
addition to the economic gain and being able to be customized
to the vaginal vault, the interstitial component vector direc-
tions can be designed with the angles obtained in a pre-plan.
Apart from this applicator repertoire, free hand interstitial
implants,31 although less frequently used for different reasons
(highly user-dependent, potentially imprecise, unstable and
loss of parallelism between vectors), can represent a helpful
choice in some special cases.32
2.1. Interstitial-vaginal applicators
Ovoids with tandem, evolutions from the classic Manches-
ter, Henschke and Fletcher applicators, modified to include
holes in the ovoids for needles insertion in order to optimize
dose coverage in parametrial invasion.33 Varian (VMS, Palo
Alto, CA, USA) has a MR compatible Fletcher type applica-
tor with vaginal interstitial component. The equivalent IS-V
applicator of Nucletron-Elekta company (Elekta, Veenendaal,
The Netherlands) (www.elekta.com/brachytherapy) is called
the Utrecht model. It resulted from collaboration with UMC
Utrecht.21,33 The applicator Fletcher CT/MR (Elekta, Veenen-
daal, The Netherlands) has had an interstitial component
added by the addition of a few holes in the ovoids, thus becom-
ing a template for guiding the needles. Each ovoid has five
holes: three located on the outer side and two additional holes
on the inner side closest to the tandem in ventral and dorsal
directions. The smallest ovoids, instead, have only had the
three outer holes pierced.
The vaginal interstitial component can be combined with
the ring endocavitary applicator,20 adapted from the clas-
sic Stockholm applicator. That is the Vienna applicator from
Elekta (Elekta, Veenendaal, The Netherlands). The Vienna
applicator is meant to be used with titanium needles. This
vendor also has an interstitial ring to be used with plastic
needles. Varian (VMS, Palo Alto, CA, USA) and Bebig (Eckert &
Ziegler, Berlin, Germany) have commercially available similar
solutions offering different ring diameters, uterine tandems
and number of inserted needles. Main features of these appli-
cators are found in Table 1.
2.2. Interstitial-perineal applicators
Commercial interstitial-perineal (IS-P) templates25 with a cer-
tain holes distribution, serve as a guide for needle insertion
across the whole perineum. Recently, Varian (VMS, Palo Alto,
CA, USA) introduced the Kelowna interstitial template, shown
in Fig. 1a. The integrated vaginal obturator is used to treat
vaginal surface and include a tandem to stretch the dose dis-
tribution to the uterine cavity.
Some users have created their own perineal templates
with cylinder and tandem, as is the case of the Benidorm
applicator.26 This applicator allows for mixing both an intra-
cavitary component (cylinder and intrauterine tube from
Elekta) and an interstitial one, commercialized by Lorca Marín
S.A, Murcia, Spain (www.lorcamarin.com), Fig. 1b, being fully
MR compatible. The template allows insertions in both parallel
(to vaginal cylinder) and divergent angles. A second tem-
plate, carved with three dimples on it, is attached to the
first one to insert three markers that simplify the recon-
struction process.34 Another institution-specific template, the
Pamplona applicator, based on the geometry of the MUPIT
applicator from Elekta (Elekta, Veenendaal, The Netherlands),
was modified to be used in MR, see Fig. 1c. The metallic parts
were replaced by plastic, and used together with the CT/MR
cylinder and the ProGuide 294 mm plastic needles from Elekta
(Elekta, Veenendaal, The Netherlands).27
2.3. Interstitial-vaginal and perineal applicators
As an example of solutions bringing together vaginal and
perineal interstitial elements (IS-V&P) in the same appli-
cator, we have the applicator M.A.C. (Mick-Alektiar-Cohen)
from Bebig (Eckert & Ziegler, Berlin, Germany) shown in
Fig. 1d. The endocavitary components consist in a tandem
and cylinder. Intrauterine tubes of 0◦ or 30◦ are available,
and vaginal obturators can be loaded to treat disease at
any vagina’s length. Interstitial component consists of up to
36 concentric channels for the placement of unilateral or
bilateral needles for the parametrium. Its main features, com-
ponents and accessories can be found in the brand catalog
(www.bebig.com).
Another example of IS-V&P applicator is the ring and tan-
dem type Venezia applicator from the vendor Elekta (Elekta,
Veenendaal, The Netherlands) shown in Fig. 1e. The applicator
enables to insert up to 134 plastic needles 6 F (2 mm) 294 mm
long, both parallel and divergent to the intrauterine probe. A
description of this applicator can be found in the reference
(https://www.elekta.com/brachytherapy/applicators.html).
3. Practical considerations about the use of
MR for cervix cancer BT
The GYN GEC-ESTRO working group published several articles
providing considerations and recommendations about the use
of MRI regarding, among other matters, appropriate strategies
for applicator reconstruction, some technical requirements,
adequate MR sequences, patient preparation and applicator
commissioning.35,36
MR facilities with magnetic field strength of 1.5 T are widely
spread. In addition, the use of 3 T MR is increasing, although
it is still rather limited. As the field strength increases, some
effects, such as warming of the applicator, larger susceptibil-
ity artifacts, especially at the tip end of titanium applicators
































Table 1 – Summary of the current commercial applicators MR compatible with interstitial component, indicating the maximum number of needles, their length and
direction as well as the potentially covered lateral dimension.
Brand model Number of needles Material Diameter Length (mm) Vaginal or
perineal





Ring 8 Plastic 1.7 mm 300 Vaginal Parallel to the tandem 20 Blunt
Mac 36 (1) Various (2) 150, 200, 300 Both Parallel to vaginal obturator 30 Sharp
Elekta
Vienna 9 (3) Titanium 1.9 mm 240 Vaginal Parallel to the tandem 19 Both
Utrecht 10 (4) Plastic 2 mm 294 Parallel to the tandem (4) 29.2
Ring 9 (3) Parallel to the tandem 19
Venezia 134 (5) Both Parallel and divergent at 20◦ 45
Varian
Fletcher 8 Plastic 2 mm 320 Vaginal Parallel to the
tandem
30 Both
3D Ring 19 (6) 39
Vienna 16 Titanium 16G 200, 250, 320 44
Style Plastic 2 mm 200, 320
Kelowna 40 Plastic 2 mm 113, 200, 320 Perineal Parallel to vaginal
obturator (7)
(8) Both
Titanium 16 G 113, 200, 250, 320 at 0◦: 27 Sharp
17 G at 90◦: 40
(1) 6 in vaginal obturator (v.o.), 11 in perineal template at 2 cm from center of v.o., 19 in perineal template at 3 cm from center of v.o.
(2) 15.5 G, 17 G, 18 G, 1.65 mm and 2.0 mm.
(3) The 30 mm and 34 mm diameter rings. The 26 mm diameter ring has inserts for 7 needles.
(4) 8 needles with cervical stopper.
(5) 6 needles in each “ovoid” and 122 in the perineal template.
(6) 12 in the ring and 7 in the tandem stopper.
(7) With the option to divert them manually.
(8) The template can be rotated 90◦ around its axis. The table shows the values in both positions.
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Fig. 1 – Applicators with perineal interstitial component. (a) Kelowna applicator (Varian), (b) Benidorm applicator (Lorca
Marín), (c) Pamplona applicator, (d) M.A.C Applicator (Bebig) and (e )Venezia applicator (Elekta).
the titanium tandem and ovoid applicator for its safe use at
3 T MR scanner.38 They used a protocol similar to the ASTM
International method for assessing radiofrequency induced
heating, magnetic displacement and induced torque.39–41
They reported difference in the rise in temperature of less than
0.5 ◦C due to the presence of the applicator placed in a phan-
tom filled with a solution of distilled water. They found no
displacement or induced torque. RF induced heating in a 3 T
MRI scanner is relatively small and the use of titanium appli-
cators seems to be safe. Nevertheless, their clinical use should
be previously verified relative to MR safety parameters.37
Some authors report the implementation into clinical rou-
tine of MR sequences for 3 T units.42,43
Adequate patient preparation is required prior to MR scan.
Although the preparation procedure may differ between cen-
ters, the use of antispasmodics is generally recommended in
order to reduce bowel motion during scanning. The use of
a saturation band is also recommended to improve contrast
in the air–fat interface of subcutaneous tissue.36 Dimopoulos
et al. also include the most relevant acquisition parameters
recommended for MR imaging.36
T2W sequences, which are the ones recommended by
GEC-ESTRO, allow a better target visualization. Ideally, the
applicator reconstruction should be performed in the same
study set as that used for contouring, thus avoiding the uncer-
tainties due to registration procedures. In some situations, the
reconstruction process may represent a challenge, for instance
when titanium applicators or interstitial vectors are used. In
such cases, additional image studies may be required. Some
authors describe the utility of T1 weighted (T1W) sequences,
3D MR images or CT images to help with this issue, as it will
be referenced forward in this report.
Special care should be taken regarding the determination
of the tip end of the catheters. The slice width employed in
axial images (usually 3–4 mm) may lead to certain inaccuracy,
which can be reduced by using additional image sequences,
such as para-sagittal44 or 3D.45
Titanium applicators and needles produce a void signal on
the MRI, the determination of the source path inside them
being therefore difficult. Furthermore, they induce suscepti-
bility artifacts, ballooning, at the end of the applicator and
needles. Many strategies are published in literature in order
to deal with this issue, as will be commented further in this
text.34,46,47
Prior to the validation of MRI for reconstruction purposes,
an assessment of the geometric distortions should be done.
These distortions are produced by inhomogeneities of the
main magnetic field, but they also may be induced by the
patient or the applicator itself. Therefore, since they are
patient and sequence dependent, they should be evaluated in
the same conditions as those used clinically. Wills et al. report
distortions below 2 mm on a 0.35 T MR.48 Wang et al.49 studied
thoroughly the sources and magnitude of geometric distort-
ions and evaluated some correction algorithms provided by
vendors. In order to reduce spatial distortions, sequences with
high gradients bandwidths should be used. When registering
MRI and CT images, special care should be taken if matching is
only based on landmark points, since this procedure is more
prone to be influenced by MRI distortions.50,51 Recently, two
articles by Torfeh et al.52,53 about the impact of the MRI geo-
metric distortions in BT of cervical cancer show distortions
below 0.5 mm in the central region, having small repercus-
sion on dose volume histograms (DVH) related parameters. A
review article by Weygand et al. has been recently published54
demonstrating a maximum distortion below 3 mm on a 1.5 T
MR unit, the magnetic susceptibility induced distortion being
smaller than the system dependent one. The largest distort-
ions are found in anatomical landmarks containing air and
soft tissue interfaces. Aubrey et al.55 report distortions of less
magnitude. They found a mean absolute system based distort-
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ions of about 1 mm in the central area and 2 mm in the outer
region. Distortions related to the presence of the applicators
were found to be about 1 mm. Domingo et al.56 reported dis-
tortions smaller than 2 mm by comparing distances in well
defined, and frequently used in obstetrics pelvimetry, bony
structures as measured on the MRI acquired at the moment of
BT and on CT images.
4. Reconstruction based on MRI
The applicator reconstruction is a step of major relevance
within the whole process of treatment planning of any BT
procedure. Clear identification of the source path inside the
catheters and the applicator is a challenge when using MRI.
Inaccuracies in the process of reconstruction may lead to
uncertainties in the dose delivered to both target and organs
at risk.35,57
Recommendations regarding the reconstruction of appli-
cators in cervical cancer BT advocate the use of MRI as
a preferred image modality since, as aforementioned, it is
advantageous to perform the reconstruction process in the
same image study employed by the physician for contouring,
which is T2W, therefore avoiding uncertainties derived from
registering procedures between different image sets.35,58
The applicator reconstruction process may be classified
mainly in two different modalities: direct and library based
reconstructions.
4.1. Direct reconstruction
This exclusive MRI reconstruction method is based on the use
of dummies, which usually consist of some kind of catheter
filled with some substance that produces a high intensity sig-
nal on MRI. Some authors report the use of a CuSO4 solution,46
saline water,44 glycerin,59 or ultrasonography gel47 as filling
substances. The signal produced by these filled catheters rep-
resents the source trajectory inside the applicator.
In a work by Schindel et al.59 seven types of agents to be
used as MRI markers are analyzed. They quantified their inten-
sity signal in both T1W and T2W images.
Adequate correspondence between actual source and
dummies trajectories should be made during commissioning.
The long-term stability of these dummies must be verified
since its characteristics may vary due, for example, to chem-
ical changes or presence of air bubbles, which will require
refilling the catheters. Adding some kind of tincture may be
useful for detecting the presence of air bubbles, which would
yield to an erroneous determination of distal dwell position
of the source, especially if they are located in the tip end. The
reconstruction is performed by following the signal produced
by the dummies throughout every slice. In many treatment
planning systems (TPS) this process can also be performed in
sagittal, coronal or user-defined reconstructed views (Fig. 2).
The direct reconstruction method is feasible when
dummies producing a high intensity signal visible on MRI are
available for the applicator under consideration. But in some
circumstances the applicator channel diameter is too small
and, therefore, the signal produced by the dummy, even if it is
available, is too weak. This would be the case of the interstitial
component of some applicators.
In case of titanium applicators, dummies are not visible
due to magnetic susceptibility artifacts. Haack et al.46 propose
a method that uses the signal of the artifact. They correlate the
positions of the artifact and the source on MRI by comparing
it with a CT scanner during commissioning. Therefore, once
the artifact is located on the MRI, the source trajectory can be
identified.
Hellebust et al.35 suggest another reconstruction method.
The void signal produced by plastic applicators on MRI con-
sists of a black area representing the external dimensions of
the applicator, but not the source path. For the reconstruction
process, a deep knowledge of the applicator geometry and the
source trajectories inside is required. During commissioning,
relative positions between external markers of the applica-
tor and some source dwell positions should be assessed, for
instance, the distance between the tip of the tandem and the
source first dwell position. Reference structures such as cav-
ities, dimples or grooves that may be recognized on MRI are
useful for reconstruction purposes if we know their positions
relative to any dwell position of the source.
In implants with interstitial component, the accurate
determination of the tip end of each needle on MRI may be an
issue. Perez-Calatayud et al.60 suggest a method for the recon-
struction of the needles in the Utrecht applicator based on the
Fig. 2 – Left: dummies filled with water. Iodine tincture is added for coloring purposes providing a better visualization of the
distal position and air bubbles. Central: sagittal view showing visualization of the dummy inside a plastic tandem. Right:
sagittal view showing visualization of the dummy inside a plastic ovoid.
reports of practical oncology and radiotherapy 2 3 ( 2 0 1 8 ) 547–561 553
Fig. 3 – Model of the Utrecht applicator with interstitial component and sagittal, axial and coronal views of reconstructed
applicator based on the TPS library.
“inserted length” of each needle as reported by the physician
at the moment of the insertion, who measures it by means of
a ruler engraved on the insertion tool. Once in the TPS, the
first step is the location of the exit point of each needle on the
ovoid surface. After that, the three views, transversal, sagittal
and coronal, should be orientated so that the needle could be
visualized in all of them. Finally, the “inserted lengthïs repro-
duced in the images with the help of the TPS ruler tool, the
needle tip being thus defined.
Adequate commissioning of each applicator is an issue of
major importance. Awunor et al.62 have quantified the system-
atic variations and uncertainties with commonly used ring
applicators, reporting source positional differences of up to
2.6 mm between ring sets of the same type and geometry.
Furthermore, another paper by Awunor et al.63 shows dif-
ferences in source position determination between different
centers using ring applicators, emphasizing the importance of
commissioning each ring before clinical use.
4.2. Library of applicators
As mentioned above, it is highly recommended that the
reconstruction of the applicator be performed in the same
image series in which the target and organs at risk have been
contoured. In general, a compromise between small slice
thickness and short acquisition times should be achieved in
order to avoid image artifacts due to patient movement dur-
ing image acquisition. However, even with a slice thickness
around 3–5 mm, visualization of the applicator can be difficult
or inaccurate in T2W images, especially in implants including
needles.
With the help of applicator libraries, which contain accu-
rate 3D models, the corresponding applicator configuration
can be imported into the TPS, translated and rotated until
the model matches the void signal produced by the applica-
tor on the MRI. This procedure is fast, simple, and less prone
to reconstruction errors, minimizing the risk of introducing
an incorrect applicator geometry (such as wrong ring diame-
ter or ovoid size) because visual verification of the applicator
reconstruction can be done directly by checking whether the
applicator void signal matches the 3D modeled applicator
shape.35 An applicator incorrectly modeled into the library will
lead to systematic errors in the reconstruction and, thus, in the
dosimetry planning. Therefore, a proper verification of each
applicator model is mandatory during the commissioning.
We should differentiate between completely rigid applica-
tors, such as the Vienna applicator, and other composed of
several parts that, even though assembled, may suffer slight
deviations respect to the model implemented in the library
during its insertion into the patient. An example of this is
the Fletcher applicator, for which the distance between ovoids
may be regulated during insertion for a better adaptation to
the vaginal size. If this is the case, each part of the applica-
tor should be reconstructed independently because relative
positions between channels are different from the modeled
applicator into the library.
Some TPS have the so-called library of applicators avail-
able. A detailed geometric model of the applicator containing
information about its external shape as well as an inter-
nal description of the source dwell positions is included in
the model. In this way, the user can fit the external shape
of the applicator to the anatomy of the patient, and the
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Fig. 4 – Left: “Ballooning” artifact at the tip end of the titanium needles. Right: reconstructed source path inside the needle
and position of the tip end of the needle.
actual information of source trajectories and dwell positions
is directly incorporated. Commercially available applicators
libraries include rigid type applicators such as Fletcher, tan-
dem and ovoids, or tandem and ring, but the interstitial
component is not implemented in them. Recently, Otal et al.61
have proposed a method to incorporate the interstitial com-
ponent of the Utrecht Applicator (Elekta, Veenendaal, The
Netherlands) into the rigid applicator library of the Oncen-
tra Brachy TPS (Elekta, Veenendaal, The Netherlands) (Fig. 3).
By means of “third-party” software, the complete geometry
of the applicator is modeled including external shape, inner
dimensions of the channels and source paths. After modeling
is completed, this model is incorporated into the applicators
library of the TPS. The user may then match the void signal
with the shape of the applicator. As the interstitial component
is also included in the model, it is also automatically incorpo-
rated in the MRI. The software tools provided by the TPS may
be used to slightly adjust the needle trajectories when they
bend.
Furthermore, a correct applicator modeling should incor-
porate the actual source path, since it does not necessarily
follow the channel center and it is applicator dependent. Ade-
quate commissioning of applicator and library must be done
to validate actual source position against applicator library.
In addition to manually matching the applicator shape and
the void signal, the use of anchor points is also a convenient
tool in the reconstruction process. Richart et al.34 suggest a
method for the in-house developed Benidorm applicator for
the treatment of advanced disease. This applicator has a major
interstitial component using titanium needles, for which an
accurate determination of the tip end in T2W MRI is often dif-
ficult due to the presence of the “ballooning” artifact (Fig. 4).
In order to determine the most distal dwell position, three A-
vitamin pellets, which produce a high intensity signal on MRI,
are embedded in the perineal template. The tip of the needle
can then be identified taking into account the inserted needle
length as measured by the physician during the insertion. The
direction of each needle is obtained by identifying the center
of the needle throughout two different slices.
Moreover, a work by Otal et al.61 shows a method to incor-
porate into the applicator library of Oncentra Brachy TPS an
applicator with a major interstitial component such as the
Benidorm template. They use these three A-vitamin pellets
as anchor points for reconstruction purposes (Fig. 5).
Schindel et al.59 introduced a novel marker flange incor-
porated to a titanium tandem applicator and filled it with a
contrast agent which can be visualized on MR images. It is
used for improving the accuracy of the reconstruction process
when using the titanium applicator.
Otal et al.65 present a method in which three capsules,
which are meant to be MRI markers, are embedded in a piece of
material, produced by a 3D printer, and attached to the Vienna-
type applicator of Bebig (Eckert & Ziegler, Berlin, Germany),
which geometry has been modeled and included into the
applicator library of Sagiplan TPS. The reconstruction is based
on the location of these markers, whose positions with respect
to the applicator geometry are accurately known, and then
using them as anchor points.
5. Other images modalities different from
T2W MR
The void signal produced by the applicators on MRI allows
localizing the applicator within the anatomy of the patient, but
frequently the source trajectories inside the applicator are not
clearly visible. As aforementioned, this problem may be solved
by modeling the applicator into a library or if dummies rep-
resenting the source paths are available, which is not always
the case. In such situations the acquisition of additional series
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Fig. 5 – Model of the Benidorm template at different levels of the axial view, showing the plate alignment and the use of the
A-vitamin pellets as anchor points. Applicator.
such as T1W, 3D MRI or CT may be necessary. Petit et al.47
use a 3D radio-frequency Spoiled Gradient known as Echo
(SPGR) sequence, with which the titanium Rotterdam tandem
and ovoid applicator are accurately reconstructed using a sin-
gle library applicator. Haack et al.46 elaborate a method for
the reconstruction of tandem and plastic ring and titanium
applicators. They study the visibility on both T2W and T1W
sequences of in-house developed MR markers filled with a
copper sulfate solution.
On many occasions, the applicators library may not be
available on the TPS. In addition, the access to MR may be
limited. The use of a complementary, or even an alternative,
image set, such as CT, may be necessary. Furthermore, there
are scenarios where the use of CT may be advantageous rel-
ative to the reconstruction of the applicator or the interstitial
needles35 or when using gadolinium in the packing gauge into
the vagina.18
Therefore, in cases of implants with titanium applicators,
or implants with an interstitial component, the reconstruction
based exclusively on MRI is challenging and may introduce
uncertainties. Tanderup et al.57 study the influence of random
and systematic uncertainties in the applicator reconstruction
by modeling translations and rotations of the applicator. They
concluded these uncertainties influence most the DVH param-
eters of the rectum and bladder and in the anterior–posterior
direction. They showed deviations in these parameters up to
5–6% per mm of applicator displacement. Schindel et al.64 ana-
lyzed the effect of the displacements of the tandem and ovoids
as a whole, and the reconstruction uncertainties induced
when shifting independently tandem and ovoids in the cranial
caudal direction. They found that D2cc of the rectum is the
most sensitive parameter to displacements, changing about
10% per ±1.5 mm shift. In order to avoid dosimetric changes
over 10%, reconstruction uncertainties must be kept within
3 mm. Kirisits et al.66 published a complete and detailed anal-
ysis of uncertainties in BT. Recently, Oonsiri et al.67 reported
small effects on DVH parameters (D90 HR-CTV and D2cc for
the rectum and bladder) of about 3% produced by reconstruc-
tion shifts of 1.3 mm.
The susceptibility artifacts induced by titanium applica-
tors make the reconstruction process difficult when it is based
on MRI exclusively, especially at the tip end of the applica-
tor or needles.35,37,46,62,68 Susceptibility artifacts are position
and sequence dependent, and may lead to low reconstruction
accuracy, which can be improved by means of an additional
CT scan.69
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Kim et al.37 evaluate the artifacts and distortions produced
by tandem and ring and tandem and ovoids in 3 T MRI, finding
the T1W sequence favorable in terms of size of the artifacts
present in the images. They report that artifacts are smaller
than 2 mm at the tip of the applicator for T1W sequences,
whereas larger distortions are found in T2W sequences (up
to 7 mm), concluding that the exclusive use of MR based BT
should be cautiously implemented. Haack et al.46 identify the
characteristic artifact produced on MRI. They correlate it to the
actual position of the source by means of a comparison with a
CT image study performed during the commissioning process.
Hu et al.70 evaluate a proton density weighted sequence (PDW)
for the case of a tandem and ovoid titanium applicator using a
1.5 T MR scanner. They show that PDW sequence enhances the
uterus-tandem contrast, consequently improving the applica-
tor reconstruction accuracy. Thus, PDW and T2W sequences
are conveniently combined for tumor delineation.
Kapur et al.42 implement the use of a 3D-balanced steady
state free precession (3D b-SSFP) sequence in a 3 T MR
scan and recognized it as the best sequence for catheter
identification. They perform the reconstruction of intra-
cavitary applicators (tandem and ovoids and tandem and
ring), intracavitary–interstitial applications (Utrecht or Vienna
Applicators) and interstitial plastic needles (freehand or with
the Syed-Neblett template). The accurate determination of the
tip end of the needles in T2W images is difficult. Besides, the
more needles are used, the worse the visibility of their tip
is, due to the ballooning artifact. The 3D b-SSFP sequence
enhances the visibility of the needle, improving the recon-
struction process. Nevertheless, the reconstruction of the
needles on MRI is time consuming and sometimes they make
use of a CT for this purpose.
In the cases in which a CT scanner is used as a supporting
image modality, the registration with MRI should be carefully
performed. It should be based on applicator geometry instead
of bony structures, and its uncertainty should be previously
assessed. Oinam et al.71 report a reconstruction method of
the tandem and ring applicator by using rigid registration
between a CT image set and MRI. They also evaluate the regis-
tration uncertainties and conclude that their impact on DVH
parameters of the bladder, rectum and sigmoid are very sen-
sitive to antero-posterior shifts. D2cc of the rectum is also
largely affected by craneo-caudal registration uncertainties.
They conclude that rigid registration of applicator between CT
and MR image studies is feasible. This “hybrid” alternative is
widely reported in literature in different modalities. Nesvacil
et al.72 implement a method that uses MR at the first fraction
and CT at the subsequent ones. Its use is limited to the case of
small tumors and intracavitary component (tandem and ring).
An applicator based image registration is performed and the
target is transferred to the CT image study. Choong et al.73 use
a similar approach with a hybrid method (MR at the first frac-
tion and CT at the following ones), reporting equivalent results
in terms of dosimetry and late toxicity compared with treat-
ments based exclusively on MRI. Similar findings are reported
for many authors.74–77 The hybrid approach represents an
alternative when access to MR is limited. Nevertheless, in
cases of large tumors or when more complex implants are
required, the hybrid approach may be suboptimal, and the use
of MRI is recommended.72
Recently, a work has been published investigating the clin-
ical outcome for patients undergoing exclusively MRI plan
treatments and comparing it with the outcome of patients
undergoing CT plan treatments. They conclude that overall
survival is significantly better in the first group while no dif-
ferences were found in terms of toxicity between the two
groups.78
Another work by Wang et al.79 make a literature review
regarding HR-CTV assessment, finding differences in HR-
CTV delineation between different image modalities. HR-CTV
width is significantly overestimated on CT and its height
underestimated. They propose that at least one MRI should
be performed for an accurate assessment of the target dimen-
sion.
6. Recent and future prospects
An image modality with an increasing and promising role is
ultrasonography (US). Besides providing good quality images
for contouring purposes of HR-CTV and organs at risk, it
has major advantages. It is a cost effective method, widely
available in clinical environment and easy to transport. Many
authors have reported the use of trans-abdominal (TAUS) or
trans-rectal ultrasound (TRUS) as a guidance method during
intraoperative insertion of intracavitary applications, as well
as a system that provides high quality images of soft tissue for
the definition of target volume.80–83 The use of US for intersti-
tial BT was reported by Stock et al.84 regarding the definition
of the target and organs at risk. Sharma et al.85 examined its
role in terms of preventing perforations of the bladder and
rectum during the needle insertion. A strong correlation in
the assessment of the volumes of the uterus and the cervix
was observed between TAUS and MRI in intracavitary BT.86
Many authors have shown the feasibility of US assisted cervix
BT compare to MRI.81,87–90 Some studies have been presented
supporting its use in terms of clinical outcomes of patients
undergoing intracavitary BT based on US imaging, showing
similar findings that MRI based procedures, following GEC
ESTRO recommendations.81,91
At the moment, although recent studies support the use of
US for contouring HR-CTV for IGABT of cervical cancer,92–94 its
exclusive use in the reconstruction process has not yet been
implemented in the case of complex and interstitial BT.
Recent work by Petric et al.95 analyzes the promising role
of the trans-cervical endosonography (TRACE) as an attractive
alternative to the MRI based cervical BT. Although impor-
tant advancements have been done about the use of US in
cervical BT, further technical developments regarding hard-
ware and software are required. Currently, the sole use of
US cannot substitute the MRI based IGABT, considered as the
gold standard.96 Recently, Banerjee et al.97 published a review
article enumerating many aspects of the use of US in BT pro-
cedures.
Another attractive field is the development of tools that
facilitate the reconstruction process of applicators and their
modeling into the applicators libraries available in the TPS.
Accurate models of applicators allow us to modify or to add
markers that can be incorporated to them and easily pro-
totyped by using a 3D printer. Sphere-shaped markers, for
reports of practical oncology and radiotherapy 2 3 ( 2 0 1 8 ) 547–561 557
example, are easy to localize in an MRI or CT sequence with an
automatic algorithm allowing a self-reconstruction process of
the applicator to be performed over the sequence of images.
Catheter reconstruction is one of the major challenges of
the whole BT procedure. A precise source path determination
is critical to achieve an accurate dosimetry. Electromagnetic
tracking (EMT) has been in use for interventional radiology,
guidance of intraoperative surgical procedures, and EBRT. Tak-
ing advantage of this experience, recently, EMT technology has
been introduced in BT procedures with the aim of improv-
ing both reconstruction and dosimetric accuracy. Initially,
this technology was used at the time of delivery to verify
the catheter spatial distribution by comparing it with that
previously assumed on the TPS, but its use in catheter recon-
struction for planning is evident and significantly promising.
Some authors have demonstrated its feasibility in interstitial
prostate BT98,99 and breast BT.100 Its role in cervical cancer BT
is still under development. Franz et al.101 and Zhou et al.102
published two review articles about the use of EMT tech-
nologies in radiation oncology BT procedures. Recently, some
works have been published evaluating the performance of
EMT systems for its use in interstitial BT, reporting an excellent
accuracy of about 1 mm.103–110
Manufacturers are working on this development because
of its high potential as a component of the HDR Units for both
verification and reconstruction assessment.
In vivo dosimetry (IVD) applied to brachytherapy has
proven its feasibility as an effective method for dose verifica-
tion, source localization and applicator reconstruction. Some
authors have published papers summarizing the dosimetry
technology available for IVD in brachytherapy.111,112. Tanderup
et al.113 explored the use of IVD for source tracking in cervix
brachytherapy. They developed a method to monitor relative
positions of applicator and dosimeters located in the rec-
tum. Source localization of a HDR source was performed by
Therriault-Proulx et al.114 by using a single-fiber multipoint
plastic scintillation detector (mPSD) in a water phantom, and
so, improving the accuracy of detection of the radioactive
source position. Nakano et al.115,116 developed an algorithm
to verify real-time source position by using a diamond detec-
tor. They achieved a resolution identifying the location of the
source below 3 mm. Kertzscher et al.117 published a review
paper in 2014, covering many aspects of the use of IVD in
brachytherapy. Recently, a feasibility study for IVD in gyne-
cological applications has been published by Van Gellekom
et al.118. They evaluate differences between measured and
predicted doses to verify the applicator configuration with
the Utrecht Interstitial Fletcher applicators. Real time IVD can
be used for source tracking during brachytherapy treatment
delivery, as showed recently by Johansen et al.119
The link of EMT with the in-vivo systems will also be a
very attractive challenge to guarantee treatment accuracy and
verification.
7. Conclusions
A review of the state of the art of the catheter reconstruc-
tion on MRI based cervix BT has been presented. The MR
compatible intracavitary and interstitial applicators have been
described together with considerations about the use of MRI
regarding correct strategies for applicator reconstruction.
Current challenges in reconstruction procedures come
from applicators having interstitial components (mainly in
the case of plastic tubes) or titanium applicators. Different
strategies have been found in the literature such as the use
of TPS libraries including the interstitial component or sup-
plementing the applicators with MR pellet markers to be used
as anchor points. The use of other images modalities differ-
ent from MR, such as CT or US, has been analyzed as well
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